spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Novolimus 

 HSMN NewsFeed - 13 May 2014
Elixir Medical Receives CE Mark Approval for the Breakthrough Fully Bioresorbable DESolve(R) 100 Novolimus Eluting Coronary Scaffold System
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 31 Oct 2013
Elixir Medical Announces Excellent 1-Year Safety and Efficacy Results for the CE-Marked Fully Bioresorbable DESolve(R) Novolimus Eluting Coronary Scaffold System
Devices Interventional Cardiology
 HSMN NewsFeed - 24 May 2013
Elixir Medical Corporation Announces Outstanding Two-Year Results from the EXCELLA BD Randomized Clinical Trial for the CE Mark-Approved DESyne(R) BD System with Biodegradable Polymer Coating
Devices Interventional Cardiology
 HSMN NewsFeed - 8 May 2013
Elixir Medical Announces FDA Approval to Commence EXCELLA III Clinical Trial with DESyne(R) Nx Novolimus Eluting Coronary Stent System in the United States
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 24 Oct 2012
Elixir Medical Corporation Announces Outstanding Three-Year Data from the EXCELLA II Randomized Clinical Trial for the CE Mark-Approved DESyne(R) System
Devices Interventional Cardiology
 HSMN NewsFeed - 28 Aug 2012
Elixir Medical Receives CE Mark Approval for the DESyne(R) BD Novolimus Eluting Coronary Stent System With Biodegradable Polymer Coating
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 16 May 2012
Elixir Medical Announces Excellent Results from DESolve I First-In-Man Study for the Fully Bioresorbable Drug Eluting Coronary Scaffold System
Devices Interventional Cardiology
 HSMN NewsFeed - 15 May 2012
Elixir Medical Announces Continued Excellent One Year Safety and Efficacy Data from the EXCELLA BD Randomized Clinical Trial for DESyne BD(TM) Novolimus Eluting Coronary Stent with Biodegradable Polymer
Devices Interventional Cardiology
 HSMN NewsFeed - 23 May 2011
Elixir Medical Receives CE Mark for DESyne(TM) Novolimus Eluting Coronary Stent System
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 17 Sep 2010
Elixir Medical Corporation Initiates Enrollment in the EXCELLA BD Randomized Clinical Trial of the Elixir Novolimus Eluting Coronary Stent System with Bioabsorbable Polymer
Devices Interventional Cardiology
 HSMN NewsFeed - 23 Sep 2009
Elixir Medical Corporation Announces Positive First-In-Man Results for Three Drug Eluting Coronary Stent Systems with Durable and Bioabsorbable Polymers
Devices Interventional Cardiology
 HSMN NewsFeed - 30 Oct 2008
SurModics Licenses Hydrophilic Coating for Elixir's Drug-Eluting and Bare Metal Stent Delivery Systems
Devices Interventional Cardiology Licensing
 HSMN NewsFeed - 16 Oct 2008
Elixir Medical Corporation Announced Positive First-In-Man Results from Three Drug Eluting Coronary Stent Systems
Devices Interventional Cardiology
 HSMN NewsFeed - 10 Oct 2008
Elixir Medical Corporation Licenses Myolimus(TM) From Novartis Pharma AG for Site-Specific Drug Delivery Applications
Devices Drug Delivery Licensing Interventional Cardiology
 HSMN NewsFeed - 1 Apr 2008
Elixir Medical Announces Positive Nine-Month Results From the Excella Novolimus-Eluting Coronary Stent System First-In-Man Study
Devices Interventional Cardiology
 HSMN NewsFeed - 22 Oct 2007
Elixir Medical Announces Positive Clinical Results for the Company's First Drug Eluting Coronary Stent
Devices Interventional Cardiology
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.